Old drug, new data: Broadening the therapeutic armamentarium for desmoid tumors
Desmoid tumours are a locally invasive neoplasm that can exhibit unpredictable clinical behaviour. While treatment options are numerous, few are supported by level 1 evidence. A recent phase 3 trial evaluated the efficacy of long-used pegylated liposomal doxorubicin in patients with progressive desmoid tumours.
Authors
- Fahima Dossa (ORCID: https://orcid.org/0000-0002-4670-7445)
- Silvia Stacchiotti
- Alessandro Gronchi
Institutions
- Cedars-Sinai Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0369
- Primary Topic
- Soft tissue tumor case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00